1. Introduction {#s0005}
===============

In December 2019, novel cases of pneumonia appeared in China, with its etiology known as SARS-CoV-2 \[[@bb0005], [@bb0010], [@bb0015], [@bb0020], [@bb0025]\], predominantly were transmitted from human-to-human \[[@bb0030],[@bb0035]\] and clinical syndrome termed as "coronavirus disease 2019 (COVID-19)", by the World Health Organization (WHO). As of 25 February 2020, there had been 78,064 laboratory-confirmed cases with 2715 fatalities caused by COVID-19, as reported in China \[[@bb0040]\]. The overall mortality rate was estimated as 3.4%, while that of critically ill patients, was 61,5% \[[@bb0045]\]. It seemed necessary to analyze the COVID-19 caused deaths and to understand the potential risk factors associated with the fatal outcomes.

In this retrospective study, we described the epidemiologic and clinical characteristics of 42 patients who died of COVID-19 infection. Hopefully, the epidemiologic data could help physicians better understand the COVID-19 infection, take appropriate actions on severe pneumonia, and reduce fatality, accordingly.

2. Materials and methods {#s0010}
========================

2.1. Participants and data collection {#s0015}
-------------------------------------

All the patients enrolled were confirmed of being infected by COVID-19. The data of the 42 confirmed COVID-19 fatalities was collected from Jan 21 to Feb 14, 2020. The data includes, demographics, clinical symptoms, laboratory findings, and treatment. All the patients were treated at Tongji Hospital Affiliated with HUST. SARS-CoV-2 infection was confirmed in accordance with the WHO interim guidelines. Data including age, gender, underlying diseases, clinical signs and symptoms, virus detection, computed tomography (CT) findings, treatments, routine blood and biochemistry, coagulation function, infection-related biomarkers, and routine urine etc., was gathered. Respiratory syncytial virus, adenovirus, and bacteria that caused pneumonia were also tested.

2.2. Statistical analysis {#s0020}
-------------------------

Descriptive analyses were performed to display potential factors that might be associated with mortality related to the COVID-19 infection. SPSS (version 22.0) software was used. Continuous data were summarized as mean ± standard deviation (SD), or median (IQR, or interquartile range), with categorical data expressed in proportions.

3. Results {#s0025}
==========

3.1. Epidemiologic characteristics and underlying diseases {#s0030}
----------------------------------------------------------

All the 42 patients who died from COVID-19, including 30 males (30/42, 71%) were included in this study ([Table 1](#t0005){ref-type="table"} ), with age distribution appeared as 69 ± 13 y (33--95 y). Of the 42 deaths, 25 (25/42, 60%) had more than one underlying known comorbidities, including 9 (9/42, 21%) with diabetes and 7 (7/42, 17%) with hypertension, 5 (5/42, 12%) with chronic cardiac or pulmonary disease, 3 (3/42, 7%) with chronic kidney disease, and 2 (2/42, 5%) with mild liver disease.Table 1Baseline characteristics and treatments of 42 patients with COVID-19 infection [⁎](#tf0005){ref-type="table-fn"}Table 1CharacteristicAll patientsAge, y69 ± 13 (33--95)GenderMale30 (71)Female12 (29)Underlying diseasesDiabetes9 (21)Hypertension7 (17)Chronic cardiac disease5 (12)Chronic pulmonary disease5 (12)Chronic kidney disease3 (7)Mild liver disease2 (5)Signs and symptomsTemperature, °C37.7 ± 1.1 (36.0--41.0)Heart rate, bpm104 ± 32 (61--189)Respiratory rate, breaths/min26 ± 8 (12--49)Systolic pressure127 ± 25 (80--180)Diastolic pressure74 ± 18 (30−120)Fever42 (100)Cough32 (76)Dyspnea32 (76)Shortness of breath30 (71)Fatigue16 (38)Chest pain14 (33)Expectoration13 (31)Conscious disturbance12 (29)Myalgia6 (14)Arthralgia4 (10)Headache3 (7)Respiratory distress3 (7)Hemoptysis3 (7)Rhinorrhea1 (2)Virus detectionNovel coronavirus42 (100)Influenza3 (7)CT findingsBilateral pneumonia42 (100)ICUOxygen therapy40 (95)Non-invasive ventilation34 (81)Tracheotomy and intubation13 (31)Invasive ventilation4 (10)Extracorporeal life support2 (5)Renal replacement therapy1 (2)[^3]

3.2. Symptoms and CT examination {#s0035}
--------------------------------

The most common symptoms appeared as fever (42/42, 100%), cough (32/42, 76%), dyspnea (32/42, 76%), shortness of breath (30/42, 71%), fatigue (16/42, 38%), chest pain (14/42, 33%), expectoration (13/42, 31%) and disturbance of consciousness (12/42, 29%). However, myalgia (6/42, 14%), arthralgia (4/42, 10%), headache (3/42, 7%), respiratory distress (3/42, 7%), hemoptysis (3/42, 7%), and rhinorrhea (1/42, 2%) appeared less frequently. All patients had undergone CT examinations and all of them presented bilateral pneumonia. Three patients were concurrently tested flu-positive.

3.3. Laboratory findings {#s0040}
------------------------

Upon admission of these patients, counts on blood cells (15 (15/39, 38%) with leucocytes, 23 (23/40, 58%) with neutrophils, 8 (8/40, 20%) with monocytes and 33 (33/40, 83%) with eosinophils) were above the normal ranges, respectively ([Table 2](#t0010){ref-type="table"} ). In 36 (36/39, 92%), 23 (23/40, 58%), 39 (39/41, 95%) and 12 (12/39, 31%) of the patients, lymphocytes, hemoglobin, albumin/globulin and platelets appeared below the normal ranges. All patients showed elevated levels of alkaline phosphatase (ALP). Higher levels of aspartate aminotransferase (AST) was seen in 51% but γ-glutamyl transpeptidase (GGT) appeared low in 49%, of the patients. However, elevated alanine aminotransferase (ALT) appeared less common.Table 2Laboratory findings of patients infected with COVID-19 on admission.Table 2Laboratory findingsNormal rangeN / N (%)Mean (SD)Median (IQR)Blood routineLeucocytes, ×10^9^/L3.50--9.503911.97 (13.69)8.07 (5.56--12.89)Increased15 (38.46)20.86 (19.16)16.75 (12.23--21.67)Neutrophils,×10^9^/L1.8--6.3408.69 (5.45)7.33 (4.52--11.38)Increased23 (57.50)12.01 (4.99)10.20 (8.00--17.40)Lymphocytes, ×10^9^/L1.1--3.2391.94 (8.30)0.63 (0.46--0.80)Increased1 (2.56)52.42 (---) ^a^52.42 (---) ^a^Decreased36 (92.31)0.58 (0.22)0.59 (0.45--0.75)Monocytes, ×10^9^/L0.1--0.6401.26 (5.31)0.38 (0.20--0.55)Increased8 (20.00)5.07 (11.67)0.88 (0.81--1.31)Eosinophils, ×10^9^/L0.02--0.52400.02 (0.07)0.00 (0.00--0.01)Increased33 (82.50)0.00 (0.00)0.00 (0.00--0.00)Red blood cell, ×10^12^/L4.3--5.8404.12 (0.66)4.14 (3.66--4.64)Decreased22 (55.00)3.62 (0.39)3.68 (3.26--3.98)Hemoglobin, g/L130.01 rang40120.48 (25.10)119.00 (107.25--140.75)Decreased23 (57.50)104.43 (21.05)110.00 (96.00--117.00)PCV, %40--50400.36 (0.06)0.36 (0.32--0.41)Decreased27 (67.50)33.37 (3.96)34.10 (30.40--35.90)Platelets, ×10^9^/L125.01 rang39162.31 (66.06)159.00 (117.00--182.00)Increased1 (2.56)392.00 (---) ^a^392.00 (---) ^a^Decreased12 (30.77)97.83 (27.05)109.50 (82.75--116.00)Blood chemistryAST, U/L≤404170.27 (120.59)41.00 (24.00--72.50)Increased21 (51.22)112.00 (158.96)70.00 (49.50--91.50)ALT, U/L≤414131.34 (19.75)24.00 (18.00--41.05)Increased10 (24.39)58.71 (21.19)49.50 (46.00--68.00)GGT, U/L7--504166.07 (87.44)42.00 (24.50--58.00)Increased6 (14.63)234.67 (135.94)161.00 (137.00--389.00)Decreased20 (48.78)23.00 (8.28)24.50 (14.50--27.00)ALP, U/L45.0--135.04182.90 (43.97)70.00 (55.50--100.00)Increased41 (100.00)82.90 (43.97)70.00 (55.50--100.00)Total protein, g/L60--804164.80 (7.08)65.40 (59.25--69.45)Decreased17 (41.46)57.98 (4.03)57.20 (55.70--61.45)BUN, mmol/L3.1--8.03713.58 (12.06)10.50 (5.56--18.00)Increased20 (54.05)20.72 (12.51)16.55 (11.04--24.08)Decreased2 (5.41)2.20 (---) ^a^2.20 (---) ^a^sCr, μmol/L59.0--104.037131.76 (144.95)89.00 (68.00--124.00)Increased13 (35.14)238.85 (207.53)140.00 (124.00--289.50)Decreased5 (13.51)42.80 (11.84)45.00 (31.00--53.50)Albumin, g/L35.0--52.04129.50 (5.08)29.90 (24.95--34.15)Decreased34 (82.93)28.05 (4.26)28.05 (24.03--31.40)Globulin, g/L20.0--35.04135.44 (5.97)36.40 (31.50--39.30)Increased21 (51.22)40.21 (2.90)39.20 (38.05--43.35)Albumin/Globulin1.5--2.5:1410.87 (0.25)0.83 (0.71--0.97)Decreased39(95.12)0.83 (0.20)0.83 (0.69--0.92)Total bilirubin, μmol/L3.4--17.14115.70 (18.66)10.30 (7.60--15.95)Increased7 (17.07)43.84 (33.65)25.50 (22.20--78.80)Glucose, mmol/L4.11--6.053810.31 (5.87)7.54 (6.14--13.35)Increased31 (81.58)11.46 (5.86)8.87 (6.94--14.66)Decreased1 (2.63)1.00 (---) ^a^1.00 (---) ^a^Calcium, mmol/L2.25--2.75412.05 (0.15)2.08 (1.92--2.14)Increased1 (2.44)2.56 (---) ^a^2.56 (---) ^a^Decreased32 (78.05)2.00 (0.11)2.02 (1.89--2.10)Phosphorus, mmol/L0.97--1.680.99 (0.27)0.98 (0.75--1.27)Decreased2 (25.00)0.65 (---) ^a^0.65 (---) ^a^Coagulation functionAPTT^b^, s29.0e rma4043.49 (8.63)41.85 (35.80--50.63)Increased19 (47.50)50.97 (5.85)51.00 (44.90--55.30)Prothrombin time^b^,s11.5--14.54016.42 (3.28)15.55 (14.58--17.40)Increased30 (75.00)17.30 (3.34)15.80 (15.28--17.90)INR^b^0.8--1.2401.32 (0.35)1.21 (1.14--1.41)Increased21 (52.50)1.50 (0.39)1.40 (1.23--1.53)Prothrombin activity^b^, %75--1254071.23 (17.40)74.00 (58.50--80.75)Increased22 (55.00)59.59 (13.39)60.00 (54.50--73.00)Fibrinogen^b^. g/L2--4405.16 (2.61)5.45 (3.72--6.23)Increased27 (67.50)6.36 (2.23)5.98 (5.43--6.75)Decreased4 (10.00)1.22 (0.46)1.34 (0.74--1.59)Infection-related biomarkersESR, mm/hMen, 0--153444.32 (23.31)39.50 (27.75--62.00)Women, 0--20Increased30 (88.24)48.90 (20.74)43.00 (34.25--62.25)Serum ferritin, ng/mL30--400282129.74 (2344.26)1330.85 (751.70--2148.48)Increased27 (96.43)2198.91 (2359.62)1396.40 (872.00--2183.00)Reactive protein, mg/L0.0 g/L25129.73 (76.37)114.10 (64.70--185.90)Increased25 (100.00)129.73 (76.37)114.10 (64.70--185.90)Serum procalcitonin, μg/L\<0.5272.13 (5.64)0.60 (0.18--1.31)Increased27 (100.00)2.13 (5.64)0.60 (0.18--1.31)Interleukin-2R, U/mL271108.93 (550.63)1006.00 (712.00--1301.00)Increased21 (77.78)1279.05 (503.32)1179.00 (960.50--1456.50)Interleukin-6, pg/mL0.0--7.027109.26 (118.55)71.96 (23.15--162.90)Increased27 (100.00)109.26 (118.55)71.96 (23.15--162.90)Interleukin-10, pg/mL2712.89 (8.95)10.90 (6.60--17.40)Increased16 (59.26)18.13 (7.86)16.80 (11.63--23.75)TNF, fmol/mL\<302712.07 (10.55)8.40 (6.70--11.60)Increased15 (55.56)16.35 (12.74)10.40 (9.30--22.20)Urine routinePH155.93 (0.42)6.00 (5.50--6.00)Red cell+(%)13 (92.86)Urinary protein+(%)14 (93.33)[^4]

Most patients showed elevated levels of infection-related biomarkers, specifically on erythrocyte sedimentation rate (ESR) (88% of cases), serum ferritin (96%), C-reactive protein (100%), and serum procalcitonin (100%) ([Table 2](#t0010){ref-type="table"}). In most patients, concentrations of interleukin (IL)-2R, IL-10, and tumor necrosis factor alpha (TNF) also showed an increase in plasma and IL-6 was elevated in all the cases. Moreover, biochemical changes were consistent with renal impairment including microscopic proteinuria (93%) and hematuria (93%), hypocalcemia (78%), hyperphosphatemia, acidosis, elevated blood urea nitrogen (54%), and serum creatinine (35%) that appeared in many of the patients. More than half of the patients presented coagulation abnormality, including elevated activated partial thromboplastin time (APTT; 48%), prothrombin time (75%), decreased prothrombin activity (55%), and/or international normalized ratio (INR; 53%). The data suggested that disseminated intravascular coagulation (DIC) was associated with the outcomes of death, in patients with COVID-19 infection.

3.4. Treatment {#s0045}
--------------

Different forms of treatment ([Table 1](#t0005){ref-type="table"}) were provided to the 42 patients at the Intensive Care Unit (ICU) of the hospital. The treatment included oxygen therapy (40/42, 95%), non-invasive ventilation (34/42, 81%), tracheotomy and intubation (13/42, 31%), invasive ventilation (4/42, 10%), extracorporeal life support (2/42, 5%), and renal replacement therapy (1/42, 2%). None of the patients ever received any experimental antiviral therapies of potential benefits during the treatment of COVID-19 infection. Patients with Flu-positive were treated with Zanamivir.

4. Discussion {#s0050}
=============

SARS-CoV-2 has been the seventh identified coronavirus, and ranking the third potentially lethal one, after SARS-CoV and MERS-CoV \[[@bb0005],[@bb0050], [@bb0055], [@bb0060], [@bb0065]\]. The present retrospective study aimed to analyze the demographic and clinical characteristics of patients who died of SARS-CoV-2 infection.

Forty-two patients died of confirmed COVID-19 infection were included in this study. In the previous studies, characteristics and fatalities of the COVID-19 infection were summarized \[[@bb0015],[@bb0070]\]. The average survival time before death was within 1--2 weeks after admission to the ICU. Patients at older age (\>65 years), with underlying diseases or ARDS were at higher risks of death \[[@bb0045]\]. Du et al. \[[@bb0075]\] identified four predictors including age ≥ 65 years, preexisting concurrent cardiovascular or cerebrovascular diseases, CD3^+^CD8^+^ T cells ≤75 cell/μL, and cardiac troponin *I* ≥ 0.05 ng/mL etc. were related to the fatality of COVID-19. In our cohort, more than half of the deaths occurred in older men with underlying diseases, especially diabetes and hypertension. However, still 40% of the deceased did not have any known underlying co-morbidity with COVID-19 infection. Common symptoms as fever, cough, expectoration, chest pain, dyspnea were all similar to reports from other researchers. However, 29% of these patients presented disturbance of consciousness, which to our knowledge, had not been mentioned in previous reports and may serve a marker for the poor outcome. Among all the patients, 3 were co-infected of flu and COVID-19, confirmed by nucleic acid testings. All the patients showed signs of bilateral pneumonia on CT examination. As for laboratory findings, lymphocytopenia appeared in more than 90% of the deaths with COVID-19 infection, suggesting that the severity of lymphocytopenia might reflect the severity of COVID-19 infection. Elevated levels of infection-related biomarkers occurred in most of the patients while the elevated level of IL-6 was observed in all the cases. Moreover, many patients showed renal impairment to some degrees. It is noteworthy that patients with abnormal blood coagulation may indicate the presence of DIC, hence increasing the risk of mortality. In terms of treatments involved, more than half of these patients received oxygen therapy and non-invasive ventilation, with a quarter of them underwent tracheotomy.

5. Conclusions {#s0055}
==============

Potential risk factors associated with COVID-19 fatalities include being male and those with underlying comorbidities. However, 40% of the patients were without any known underlying comorbidities. Lymphopenia, ALP, high serum ferritin, hypoalbuminaemia/globulinaemia, C-reactive protein, serum levels of procalcitonin, IL-6, and markers of renal dysfunction appeared common in these patients. It must also be mentioned that more than half of the patients presented clotting abnormalities, which might serve as a marker for poor prognosis.

We hope that the information we have provided could highlight those conditions related to early warning on the risk of the COVID-19 fatalities, so as to reduce both the incidence of critical illness and mortality.
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